Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:DBV NASDAQ:FBLG OTCMKTS:HIPH NYSE:NNVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AFBLGFibroBiologics$0.54-3.4%$0.71$0.53▼$4.41$23.26M-0.74513,640 shs361,418 shsHIPHAmer Prem Water$0.00$0.00▼$0.00$6.44M2.111.73 million shsN/ANNVCNanoViricides$1.59+0.6%$1.51$0.94▼$2.34$25.55M0.96250,678 shs96,727 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%FBLGFibroBiologics-3.40%-15.49%-11.34%-36.07%-85.54%HIPHAmer Prem Water0.00%0.00%0.00%+∞-50.00%NNVCNanoViricides+0.63%-5.36%+15.22%+12.77%-22.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AFBLGFibroBiologics3.0267 of 5 stars3.64.00.00.01.52.50.6HIPHAmer Prem WaterN/AN/AN/AN/AN/AN/AN/AN/ANNVCNanoViricides0.497 of 5 stars0.05.00.00.01.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AFBLGFibroBiologics 3.20Buy$13.002,323.56% UpsideHIPHAmer Prem Water 0.00N/AN/AN/ANNVCNanoViricides 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HIPH, DBV, NNVC, and FBLG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $12.008/4/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.007/29/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.007/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/A$0.02 per shareN/AHIPHAmer Prem Water$70K0.00N/AN/AN/ANaNNNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AFBLGFibroBiologics-$11.16M-$0.36N/AN/AN/AN/A-710.25%-118.02%N/AHIPHAmer Prem WaterN/AN/A0.00N/AN/AN/AN/AN/AN/ANNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ALatest HIPH, DBV, NNVC, and FBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q1 2025FBLGFibroBiologics-$0.11-$0.12-$0.01-$0.12N/AN/A5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/AHIPHAmer Prem WaterN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AFBLGFibroBiologicsN/A0.930.93HIPHAmer Prem WaterN/AN/AN/ANNVCNanoViricidesN/A3.442.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVInvesco DB G10 Currency Harvest Fund85.24%FBLGFibroBiologicsN/AHIPHAmer Prem WaterN/ANNVCNanoViricides10.30%Insider OwnershipCompanyInsider OwnershipDBVInvesco DB G10 Currency Harvest FundN/AFBLGFibroBiologics20.00%HIPHAmer Prem WaterN/ANNVCNanoViricides4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableFBLGFibroBiologics1041.89 million33.51 millionN/AHIPHAmer Prem Water164.40 billionN/ANot OptionableNNVCNanoViricides2016.07 million14.92 millionOptionableHIPH, DBV, NNVC, and FBLG HeadlinesRecent News About These CompaniesNanoViricides says antiviral candidate NV-387 could address global measles surgeJuly 30, 2025 | proactiveinvestors.comMeasles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricidesJuly 30, 2025 | accessnewswire.comANanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387July 23, 2025 | proactiveinvestors.comNanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive ValueJuly 23, 2025 | accessnewswire.comAMeasles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricidesJuly 21, 2025 | usatoday.comNanoViricides says lead antiviral boosted survival in measles-infected miceJuly 21, 2025 | proactiveinvestors.comMeasles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricidesJuly 21, 2025 | accessnewswire.comANanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox diseaseJuly 18, 2025 | pharmabiz.comPWHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16, 2025 | azcentral.comANanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergencyJuly 16, 2025 | proactiveinvestors.comWHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16, 2025 | accessnewswire.comANanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15, 2025 | proactiveinvestors.comNanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15, 2025 | proactiveinvestors.comNNVC: NanoViricides Set to Initiate Phase 2 Trial in MPoxJuly 15, 2025 | finance.yahoo.comNanoViricides nears completion of clinical trial design for MPox treatmentJuly 14, 2025 | proactiveinvestors.comAdaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricidesJuly 14, 2025 | markets.businessinsider.comNanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health CaseJuly 7, 2025 | theglobeandmail.comNanoViricides advances antiviral candidate NV-387 into Phase 2 trials for MpoxJuly 2, 2025 | proactiveinvestors.comNanoViricides Inc.June 19, 2025 | barrons.comNanoViricides touts antiviral NV-387 as tool against new COVID variantJune 18, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHIPH, DBV, NNVC, and FBLG Company DescriptionsInvesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.FibroBiologics NASDAQ:FBLG$0.54 -0.02 (-3.40%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$0.55 +0.01 (+2.54%) As of 08/6/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Amer Prem Water OTCMKTS:HIPHAmerican Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.NanoViricides NYSE:NNVC$1.59 +0.01 (+0.63%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$1.66 +0.08 (+4.72%) As of 08/6/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
